Drug intelligence / Profile preview

WH602

Development stage: Preclinical
Lead developer: Novan
Modality: Nanoparticles → Drug Delivery Systems, Small Molecules
Administration: Intravaginal

Overview

WH602 is an investigational nitric oxide–releasing intravaginal product being developed by Novan for the treatment of cervical intraepithelial neoplasia and high‑risk human papillomavirus (HPV) infections. Built on Novan’s nitric oxide platform, the formulation (developed as both gel and suppository concepts) is intended to deliver sustained, localized nitric oxide to the cervical and vaginal mucosa to exert antiviral and potentially immunomodulatory effects against oncogenic HPV while minimizing systemic exposure.[3][5][11][13]

Beyond the preview

Go deeper on WH602.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on WH602.

Explore the full profile